Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder

Heinz LäubliDepartment of Internal Medicine, Division of Medical Oncology, University Hospital Basel, Switzerland, ;Department of Biomedicine, Cancer Immunology Laboratory, University Hospital Basel, Switzerland, Correspondence[email protected]

Alexandar TzankovInstitute of Pathology, University Hospital Basel, Switzerland, and

Darius JuskeviciusInstitute of Pathology, University Hospital Basel, Switzerland, and

Lukas DegenDivision of Gastroenterology and Hepatology, University Hospital Basel, Switzerland

Christoph RochlitzDepartment of Internal Medicine, Division of Medical Oncology, University Hospital Basel, Switzerland,

Frank Stenner-LiewenDepartment of Internal Medicine, Division of Medical Oncology, University Hospital Basel, Switzerland, ;Department of Biomedicine, Cancer Immunology Laboratory, University Hospital Basel, Switzerland,

Click to increase image sizeClick to decrease image size

Acknowledgements

We thank the patient and her family for letting us publish her case in this report.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder

Potential conflict of interest

Information for

Open access

Opportunities

Help and information

Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder

Acknowledgements

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature